Hispanic Patients May Have Increased Risk of CRS After CAR T-Cell Therapy
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR T-cell therapy outcomes in patients with B-ALL.
All articles by Lauren Dembeck, PhD
Quadruplet Produces Deep Responses in High-Risk, Newly Diagnosed Multiple Myeloma
Isatuximab plus carfilzomib, lenalidomide, and dexamethasone can produce deep responses in patients with high-risk, newly diagnosed multiple myeloma, a phase 2 trial suggests.
Monoclonal Antibody Shows Promise for Treating MPNs in Preclinical Study
Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.
Salvage Chemotherapy Before Allo-HSCT Does Not Improve Outcomes in Rel/Ref AML
Salvage chemotherapy before allogeneic transplant does not improve outcomes in relapsed/refractory acute myeloid leukemia, a phase 3 study suggests.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Less May Be More When Treating Newly Diagnosed AML
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Teclistamab Plus Daratumumab and Lenalidomide Shows Promise in Rel/Ref Multiple Myeloma
Teclistamab plus daratumumab and lenalidomide produced deep and durable responses in patients with relapsed or refractory multiple myeloma.
Platinum Chemo “Should Be Standard” for Younger Patients With TNBC
Adding carboplatin to standard neoadjuvant chemotherapy improved outcomes in younger patients with triple-negative breast cancer.
Cemiplimab Plus REGN3767 and Chemo Shows Promise for HER2- Breast Cancer
Combination cemiplimab, REGN3767, and chemotherapy appears effective in triple-negative breast cancer and HR+, HER2- breast cancer.
Palbociclib Does Not Improve PFS After Progression on CDK4/6 Inhibitors, ET
Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast cancer.
- Loading...
Loading...
Next post in SABCS 2022
Loading... 
Loading...